Last reviewed · How we verify
TPM XR
At a glance
| Generic name | TPM XR |
|---|---|
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phentermine/Topiramate for Uric Acid Stones (PHASE3)
- Therapy for Migraine Prevention in Children 6-11 Years of Age (PHASE4)
- A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (PHASE3)
- Anti-obesity Pharmacotherapy and Inflammation
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (PHASE4)
- Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine (PHASE2)
- A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence (PHASE2)
- Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPM XR CI brief — competitive landscape report
- TPM XR updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI